1. Home
  2. CRGY vs BLLN Comparison

CRGY vs BLLN Comparison

Compare CRGY & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Energy Company

CRGY

Crescent Energy Company

N/A

Current Price

$11.62

Market Cap

5.5B

Sector

Energy

ML Signal

N/A

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

N/A

Current Price

$109.76

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRGY
BLLN
Founded
1986
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.6B
IPO Year
2022
2025

Fundamental Metrics

Financial Performance
Metric
CRGY
BLLN
Price
$11.62
$109.76
Analyst Decision
Buy
Buy
Analyst Count
17
8
Target Price
$18.69
★ $128.29
AVG Volume (30 Days)
★ 8.5M
546.0K
Earning Date
11-02-2026
11-04-2026
Dividend Yield
★ 4.31%
N/A
EPS Growth
N/A
★ 103.40
EPS
N/A
★ 0.81
Revenue
★ $3,579,782,000.00
$305,112,000.00
Revenue This Year
$41.06
$51.61
Revenue Next Year
$23.05
$24.03
P/E Ratio
★ $99.08
$137.53
Revenue Growth
22.14
★ 99.97
52 Week Low
$7.68
$61.96
52 Week High
$15.47
$150.44

Technical Indicators

Market Signals
Indicator
CRGY
BLLN
Relative Strength Index (RSI) 38.19 50.32
Support Level $11.45 $89.26
Resistance Level $11.69 $119.20
Average True Range (ATR) 0.53 6.10
MACD -0.25 0.01
Stochastic Oscillator 28.67 47.35

Price Performance

Historical Comparison
CRGY
BLLN

About CRGY Crescent Energy Company

Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The company operates in one reportable segment, which is the exploration and production of crude oil, natural gas, and NGLs.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: